|
EP2186524B1
(en)
|
2001-05-25 |
2018-02-21 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
|
|
EP4091624A1
(en)
|
2013-03-15 |
2022-11-23 |
Protagonist Therapeutics, Inc. |
Hepcidin analogues and uses thereof
|
|
US12383518B2
(en)
|
2013-11-03 |
2025-08-12 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Disulfide-masked pro-chelator compositions and methods of use
|
|
WO2019018377A1
(en)
*
|
2017-07-18 |
2019-01-24 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
DISULFIDE-MASKED PRO-CHELATE COMPOSITIONS AND METHODS OF USE
|
|
US11504346B2
(en)
|
2013-11-03 |
2022-11-22 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Redox-activated pro-chelators
|
|
CA2949215C
(en)
|
2014-05-16 |
2023-03-14 |
Protagonist Therapeutics, Inc. |
.alpha.4.beta.7 integrin thioether peptide antagonists
|
|
SG10201810154WA
(en)
|
2014-07-17 |
2018-12-28 |
Protagonist Therapeutics Inc |
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
|
|
JP2017535527A
(ja)
|
2014-10-01 |
2017-11-30 |
プロタゴニスト セラピューティクス， インコーポレイテッド |
新規のα４β７ペプチド単量体及び二量体拮抗薬
|
|
WO2016054445A1
(en)
|
2014-10-01 |
2016-04-07 |
Protagonist Therapeutics, Inc. |
Novel cyclic monomer and dimer peptides having integrin antagonist activity
|
|
US10787490B2
(en)
|
2015-07-15 |
2020-09-29 |
Protaganist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
CA3009834A1
(en)
|
2015-12-30 |
2017-07-06 |
Protagonist Therapeutics, Inc. |
Analogues of hepcidin mimetics with improved in vivo half lives
|
|
EP3399996A4
(en)
*
|
2016-01-08 |
2019-10-16 |
La Jolla Pharmaceutical Company |
METHOD FOR THE ADMINISTRATION OF HEPCIDINE
|
|
CA3017926C
(en)
|
2016-03-23 |
2023-10-10 |
Protagonist Therapeutics, Inc. |
Methods for synthesizing .alpha.4.beta.7 peptide antagonists
|
|
WO2018022937A1
(en)
|
2016-07-27 |
2018-02-01 |
Protagonist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
|
|
AU2017324446A1
(en)
*
|
2016-09-06 |
2019-03-28 |
La Jolla Pharmceutical Company |
Methods of treating iron overload
|
|
CA3047320A1
(en)
*
|
2016-12-19 |
2018-06-28 |
La Jolla Pharmaceutical Company |
Methods of administering hepcidin
|
|
WO2018128828A1
(en)
|
2016-12-23 |
2018-07-12 |
Bayer Healthcare Llc |
Novel hepcidin mimetics and uses thereof
|
|
EP3681900A4
(en)
|
2017-09-11 |
2021-09-08 |
Protagonist Therapeutics, Inc. |
OPIOID AGONIST PEPTIDES AND THEIR USES
|
|
WO2019157268A1
(en)
*
|
2018-02-08 |
2019-08-15 |
Protagonist Therapeutics, Inc. |
Conjugated hepcidin mimetics
|
|
CA3104418A1
(en)
|
2018-07-12 |
2020-01-16 |
Protagonist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
ES2934492T3
(es)
|
2018-12-13 |
2023-02-22 |
Global Blood Therapeutics Inc |
Inhibidores de ferroportina y métodos de uso
|
|
CA3139209A1
(en)
|
2019-05-07 |
2020-11-12 |
Bayer Aktiengesellschaft |
Masp inhibitory compounds and uses thereof
|
|
AU2020311395A1
(en)
|
2019-07-10 |
2022-02-03 |
Protagonist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
US20220372099A1
(en)
|
2019-09-03 |
2022-11-24 |
Protagonist Therapeutics, Inc. |
Conjugated hepcidin mimetics
|
|
CA3156007A1
(en)
*
|
2019-09-27 |
2021-04-01 |
Disc Medicine, Inc. |
METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
|
|
US20220372136A1
(en)
*
|
2019-09-27 |
2022-11-24 |
Disc Medicine, Inc. |
Methods for treating anemia of chronic disease
|
|
MX2022008740A
(es)
|
2020-01-15 |
2022-09-23 |
Janssen Biotech Inc |
Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
|
|
SMT202500254T1
(it)
|
2020-01-15 |
2025-09-12 |
Janssen Biotech Inc |
Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
|
|
CA3181577A1
(en)
|
2020-04-28 |
2021-11-04 |
Global Blood Therapeutics, Inc. |
Thieno pyrimidines as ferroportin inhibitors
|
|
CA3181583A1
(en)
|
2020-04-28 |
2021-11-04 |
Global Blood Therapeutics, Inc. |
Methods of use for pyrimidines as ferroportin inhibitors
|
|
US11746100B2
(en)
|
2020-04-28 |
2023-09-05 |
Global Blood Therapeutics, Inc. |
Cycloalkyl pyrimidines as ferroportin inhibitors
|
|
ES3075793T3
(en)
|
2020-05-13 |
2026-08-07 |
Disc Medicine Inc |
Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
|
|
AU2021273014A1
(en)
|
2020-05-13 |
2022-11-17 |
AbbVie Deutschland GmbH & Co. KG |
Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
|
|
CN111560051B
(zh)
*
|
2020-05-26 |
2022-11-25 |
大连工业大学 |
一种具有促铁吸收活性的虾源九肽及其应用
|
|
KR20230035082A
(ko)
*
|
2020-07-02 |
2023-03-10 |
탐페레 유니버시티 파운데이션 에스알 |
헵시딘의 레닌-기반 분석
|
|
IL299530A
(en)
*
|
2020-07-28 |
2023-02-01 |
Protagonist Therapeutics Inc |
Psidine is a conjugated mimetic
|
|
CN114252627A
(zh)
*
|
2020-09-24 |
2022-03-29 |
首都医科大学附属北京世纪坛医院 |
尿液铁调素及其多肽片段在过敏性疾病中的应用
|
|
AU2021383828A1
(en)
|
2020-11-20 |
2023-07-06 |
Janssen Pharmaceutica Nv |
Compositions of peptide inhibitors of interleukin-23 receptor
|
|
WO2022212696A1
(en)
*
|
2021-04-01 |
2022-10-06 |
Protagonist Therapeutics, Inc. |
Conjugated hepcidin mimetics
|
|
CA3220871A1
(en)
*
|
2021-06-14 |
2022-12-22 |
Protagonist Therapeutics, Inc. |
Hepcidin mimetics for treatment of hereditary hemochromatosis
|
|
KR20240034224A
(ko)
|
2021-07-14 |
2024-03-13 |
얀센 바이오테크 인코포레이티드 |
인터류킨-23 수용체의 지질화된 펩티드 억제제
|
|
CN115703826B
(zh)
*
|
2021-08-03 |
2025-05-06 |
浙江大学 |
铁调素改造体及其应用
|
|
EP4536683A4
(en)
*
|
2022-06-07 |
2026-06-10 |
Protagonist Therapeutics Inc |
HEPCIDINE MIMETIC AGENTS FOR THE TREATMENT OF SICKLE CELL DISEASE
|
|
US20260224514A1
(en)
*
|
2022-09-15 |
2026-08-06 |
Migal Galilee Research Institute Ltd. |
Site-specific activation of regulatory t cells
|
|
WO2025224128A1
(en)
|
2024-04-24 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Methods of treatment of iron overload associated diseases by administration hepcidin locally in the gut
|